Scrip
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
in the expanding and competitive field of obesity therapy clinical trials, one trend is increasingly causing a headache: placebo-arm participants dropping out or using “off-protocol” weight-loss treatments while on trial.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.
Other top 20 players also moved up in the rankings fired by double-digit growth. Lilly, Novo Nordisk and Amgen all gained on the Scrip 100, which is based on FY 2024 pharmaceutical sales.
Scrip 100 Rankings Shake-Up: AstraZeneca, Lilly, Novo Nordisk And Amgen Climb Higher - Clone - Clone
Other top 20 players also moved up in the rankings fired by double-digit growth. Lilly, Novo Nordisk and Amgen all gained on the Scrip 100, which is based on FY 2024 pharmaceutical sales.
Other top 20 players also moved up in the rankings fired by double-digit growth. Lilly, Novo Nordisk and Amgen all gained on the Scrip 100, which is based on FY 2024 pharmaceutical sales.
Other top 20 players also moved up in the rankings fired by double-digit growth. Lilly, Novo Nordisk and Amgen all gained on the Scrip 100, which is based on FY 2024 pharmaceutical sales.
Other top 20 players also moved up in the rankings fired by double-digit growth. Lilly, Novo Nordisk and Amgen all gained on the Scrip 100, which is based on FY 2024 pharmaceutical sales.
Other top 20 players also moved up in the rankings fired by double-digit growth. Lilly, Novo Nordisk and Amgen all gained on the Scrip 100, which is based on FY 2024 pharmaceutical sales.
Other top 20 players also moved up in the rankings fired by double-digit growth. Lilly, Novo Nordisk and Amgen all gained on the Scrip 100, which is based on FY 2024 pharmaceutical sales.
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
Lupin’s CEO Vinita Gupta and MD Nilesh Gupta outline the company’s innovation agenda, strategy on GLP-1 drugs including fortnightly candidate bofanglutide, plans to get to number one in the domestic market and the legacy of their father in this podcast interview.
Also, Latest News From Europe, Canada, Saudi Arabia, Finland, China, And The US